Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
University of Washington
Ohio State University Comprehensive Cancer Center
Mayo Clinic
Emory University
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Roswell Park Cancer Institute
Mayo Clinic
University of Southern California
Mayo Clinic
Mayo Clinic
Mayo Clinic
Emory University
Mayo Clinic
Mayo Clinic
City of Hope Medical Center
Mayo Clinic
Mayo Clinic
Mayo Clinic
Mayo Clinic
University of California, San Francisco
Roswell Park Cancer Institute
Mayo Clinic
Academic and Community Cancer Research United
Mayo Clinic
Emory University
Ohio State University Comprehensive Cancer Center
University of California, San Francisco
Mayo Clinic
Mayo Clinic
Mayo Clinic
Mayo Clinic
University of Southern California
Academic and Community Cancer Research United
University of Washington
M.D. Anderson Cancer Center
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Mayo Clinic
Fred Hutchinson Cancer Center
Mayo Clinic
Mayo Clinic
OHSU Knight Cancer Institute
Barbara Ann Karmanos Cancer Institute
University of Pittsburgh
Barbara Ann Karmanos Cancer Institute